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Abstract 
Neurotensin derivatives having a dioctadecyl group were synthesized and immobilized on DMPC liposome to construct a 
multivalent-ligand system. The derivatives are Ac-Glu[N(C 18 H 37)2 ]-(Sar-Sar-Pro)n-Arg-Arg-Pro-Tyr-Ile-Leu-OH (D3nNT, n = 0,1,2,3), 
where a dioctadecyl group was connected to the N-terminal side of neurotensin 8-13 fragment directly or through a hydrophilic and 
flexible spacer chain of different lengths. The derivatives were spontaneously immobilized on DMPC liposome upon incubation 
overnight. The receptor affinity of the derivatives increased significantly upon immobilization on liposome. The maximum affinity was 
obtained by D9NT immobilized on DMPC liposome at the molar ratio of DMPC and D9NT of 200. This affinity is slightly better than the 
neurotensin 8-13 fragment, the message segment of the derivatives. The fluorescent microscopy using rhodamine-labelled liposome 
revealed that the multivalent-ligand system binds to specific receptors without dissociation of the derivative from DMPC liposome. 
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1. Introduction 
Endogenous peptide hormones are signaling molecules 
which regulate the activities of the endocrine system and 
the nervous ystem. The importance of medicinal applica- 
tion of the peptides will be extensively increasing in near 
future, because of the high pharmacological efficiency and 
Abbreviations: Ac, acetyl group; Boc, N~-t-butyloxycarbonyl; BOP, 
benzotriazol- 1 yloxy-tris(dimethylamino)phosphonium hexafluorophos- 
phate; BzC12, 2,6-dichlorobenzyl; D3nNT, Ac-Glu[N(C18H37):]- 
(S'S'P),-RRPYIL (n = 0,1,2,3); DCC, dicyclohexylcarbodiimide; 
DMEM, Dulbecco's modified Eagle's medium; DMF, dimethylform- 
amide; DMPC,dimyristoylphosphatidylcholine; DPPE, dipalmitoylphos- 
phatidylethanolamine; EDTA, ethylenediaminetetraacetic acid; EGTA, 
ethylene glycol bis([3-aminoethyl ether)-N,N,N',N'-tetraacetic acid;HAT, 
a mixture of hypoxanthine, aminopterin and thymidine(10 mM/0.1 
raM/1.6 mM); Hepes, N-2-hydroxylethylpiperazine-N'-2-ethanesulfonic 
acid; HOBt, N-hydroxybenzotriazole; HPLC, high performance liquid 
chromatography; IC50, the ligand concentration necessary to occupy the 
half of the binding sites of receptor; MSA, methanesulfonic a id; Mts, 
2,4,6-trimethylbenzenesulfonyl; NT, neurotensin; OEt, ethyl ester; 
PBS(-), phosphate-buffered saline without Ca 2+ and Mg 2÷ ions; Rho- 
DPPE, Rhodamine-labelled DPPE; S', sarcosine; Tes, N-tris(hydroxy- 
methyl)-2-aminoethanesulfonic ac d; TFA, trifluoroacetic acid; TLC, 
thin-layer chromatography; Tris, tris(hydroxymethyl)aminomethane. 
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low toxicity or side effects in administration [1]. Many 
attempts have been made to reduce the molecular size of 
peptide hormones to the minimum-essential length for the 
pharmaceutical ctivity [2], to increase resistance against 
biodegradation in vivo [3], and to decrease undesired side 
effects due to antigenicity [4]. 
Construction of divalent or multivalent peptidic ligands 
can be a way to control biological activities of peptide 
hormones. Divalent ligands are the conjugate of two mes- 
sage segments of the same kind or different kinds of 
peptide hormones through a spacer chain of different 
lengths. It has been reported that divalent ligands showed 
unique receptor selectivity [5] or activated a biologically 
low-potent peptide toward opioid receptor [6]. These bio- 
logical effects of bivalent ligands might have arisen from 
simultaneous binding to two types of receptors which are 
separated in a distance suitable for cross-linking by the 
divalent ligand. An example of multivalent ligand has been 
reported, in which several molecules of ct-melanophore- 
stimulating hormone (et-MSH) are connected to tobacco 
mosaic virus (TMV) [7]. The multivalent ligand showed an 
enhanced receptor affinity due to multisite interaction be- 
tween TMV and receptors in cell membrane. The idea of 
multisite interaction should be useful for designing peptide 
conjugate with controlled biological activities [8]. 
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We have investigated poly(lysine) [9] and dextran [10] 
for the carrier of enkephalin molecules. However, the 
receptor affinity of the multivalent system on the basis of 
an enkephalin unit was lower than the enkephalin itself, 
probably due to steric hindrance of the carrier molecule 
against he interaction of the enkephalin unit with recep- 
tors in membrane. On the other hand, a multivalent system 
using liposome as the carrier, to which enkephalin 
molecules carrying long alkyl chains were immobilized, 
showed high receptor affinity because of low steric hin- 
drance of liposome in multisite binding to receptors [11]. 
The enkephalin derivatives having long alkyl chains were 
spontaneously incorporated into the liposome by incuba- 
tion. This state is represented by 'immobilization of ligand 
on the surface of liposome', although the ligand is allowed 
a 2-dimensional diffusion. 
In the present study, we applied the liposomal multiva- 
lent ligand system to neurotensin, which differs from 
enkephalin in the following points: (i) different signal 
transduction systems (the signal transmission by cAMP-de- 
pendent protein kinase for enkephalin [12] and by protein 
kinase C for neurotensin [13]), (ii) the high affinities of 
enkephalin by the N-terminal ammonium group [14], and 
neurotensin by the C-terminal carboxyl group [15]. There- 
fore, long alkyl chains were connected to C terminal of 
enkephalin and to N terminal of neurotensin as anchoring 
group for immobilization. The effectiveness of multivalent 
ligand system consisting of peptide hormones immobilized 
on liposome should be established not only with enkephalin 
but also with neurotensin. 
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2. Materials and methods 
2.1. Materials 
Protected amino acids were purchased from Kokusan 
Chemical Works, Japan. 3H-labeled neurotensin was ob- 
tained from DuPont/NEN Research Products, USA. The 
GF/C  filters used for binding assay were purchased from 
Whatman, UK. Neurotensin and DMPC were purchased 
from Sigma, USA. Rhodamine-labelled DPPE was pur- 
chased from Molecular Probes, USA. Other chemicals 
were of highest purity commercially available. 
2.2. Synthesis 
Syntheses of the neurotensin fragment, the spacer pep- 
tides and the neurotensin derivatives were carried out by a 
conventional liquid-phase method. The synthetic schemes 
are shown in Fig. 1. All the protected intermediates were 
purified by an LH20 column using methanol as eluant. All 
intermediates and final compounds were identified by 1H- 
NMR, and the purity was checked by TLC. Analytical 
TLC was performed on Merck silica gel 60 F25 4 aluminum 
plates with detection by UV light and/or the ninhydrin 
Boc-(S'S'P)a-OBzl Boc-R (Mrs) R(Mts)PY0szC;2) IL-OFA 
(n= 1,2,3) 
H-(S'S'P)~-OB~ 
(n= 1,2,31 
/ Ac.E(~Is).O H TFA 
~ DCCfHOBt 
Ac-E(2CIs)- (S 'S 'P)n-OBzl 
(n = 1,2 ,3)  
I Pd/C 
Ac-E(2CIs)-(S'S'P)~-OH (TFA) R (Mrs) R fMts )PY~ IL-OEt 
(n = 0,1, 2,3) 
Ae-E(2CIs)-(S'S 'P)n-R(M~) R~Y~m~011.~F_~ 
(n = o, 1, 2, 3) 
l)~woteettom 
Ac-E(2Ct s)-(S'S 'P)n-RRPYIL-OH 
(n=0,1 ,  2~ 3) 
Fig. 1. Synthetic scheme of (A) the protected hexapeptide (neurotensin 
8-13 fragment), (B) the hydrophilic oligopeptide (spacer chain), and (C) 
the neurotensin derivatives. 
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test. The solvent systems of TLC were as follows: (I), 
CHC13/metbanol/aqueous ammonia= 65:25:5, v /v /v ;  
(II), n-butanol/acetic a id/water = 10:1:3, v /v /v .  
Coupling reactions were carried out by using DCC and 
HOBt except he coupling between Ac-E(2C~8)-(S'S'P) .- 
OH and R(Mts)R(Mts)PY(BzCI2)IL-OEt, for which BOP 
and HOBt were used as coupling reagents. 
The protecting roups, Mts, Boc and BzCI 2 were re- 
moved by MSA in the presence of thioanisole, o-cresol, 
and anisole ([MSA]/[thioanisole]/[o-cresol]/[anisole] = 
0.75:0.25:0.05:0.05, v /v /v /v ) .  The amount of MSA was 
50-fold of that of protecting roup. Ethyl ester was depro- 
tected by hydrolysis in methanol/dioxane (1:1, v /v)  with 
2 molar-equivalent of NaOH. The final products were 
purified by a partition chromatography using a Sephadex 
G-50 column, which was prepared by an lower phase of a 
mixture of n-butanol/acetic acid/water (5:1:4, v /v /v ) .  
The samples were eluted by the upper phase of the mix- 
ture. The main fraction was collected, and purified further 
by a preparative HPLC using a reverse-phase column. The 
eluant composition of water/CH3CN/TFA was changed 
from 40:60:0.05 to 0:100:0.05 over 20 min. The product 
was lyophilized. 
The purification of the final products of the neurotensin 
derivatives was carried out by HPLC under following 
conditions: column, 5C18-AR (10 × 250, Nakalai Tesque, 
Japan) ;  f low rate, 3 ml /min ;  grad ient ,  
water/CH3CN/TFA from 40:60:0.05 to 0:100:0.05 over 
20 min. 
The properties of the neurotensin derivatives (D3nNT, 
n = 0,1,2,3) are as follows. Neurotensin 8-13 fragment: 
TLC (I), Rf = 0.66; TLC(II), Rf = 0.59; HPLC, 3.6 min. 
The amino-acid analysis of the product: 1.00 Leu, 1.00 Ile, 
0.99 Tyr, 1.00 Pro and 2.00 Arg. DONT: TLC(I), Rf = 0.25; 
TLC(II), R t = 0.21; HPLC, 13.4 min; ~H-NMR (400 MHz, 
CDCI 3, 23°C) 8 0.85 (m, 18H, Leu C~H3, Ile C~H3, 
C~H3 and acyl chains CH3), 1.24 (s, 64H, acyl chains 
CH2), 1.55-1.8 (b, 14H, lie CISH, C~H2, Leu C~H2, 
CVH and Arg C~H2,C~H2), 1.8-2.3 (b, I1H, acetyl CH 3, 
Pro and Glu CI3H2,C~H2), 2.5-2.9 (s, 2H, Tyr CI3H2), 
2.9-3.7 (b, 10H, Pro C~H2, Arg C~H2 and acyl chains 
C~H2), 4.1-4.6 (b, 7H, Tyr, Arg, Pro, Glu, Ile and Leu 
C ~ H), 6.7-7.2 (b, 4H, Tyr +), 7.5-7.7 (m, 6H, Arg, Leu, 
Ile,Glu, Tyr NH). D3NT: TLC(I), Rf = 0.7; TLC(II), Rf = 
0.37; HPLC, 12.8 min. ~H-NMR data were the same as 
those of D9NT except of proton intensities of Sar and Pro 
residues. D6NT: TLC(I), Rf = 0.71; TLC(II), Rf = 0.42; 
HPLC, 12.4 min. J H-NMR data were the same as those of 
D9NT except of proton intensities of Sar and Pro residues. 
D9NT: TLC(I), Rf=0.78; TLC(II), Rf=0.39; HPLC, 
12.2 rain; IH-NMR (400 MHz, CDC13, 23°C) ~ 0.85 (m, 
18H, Leu C8H3, Ile C~H3 , C~H3 and acyl chains CH3), 
1.24 (s, 64H, acyl chains CH2), 1.5-2.7 (b, 39H, Ile C~H, 
C~H2, Leu C~H2, C~H, acetyl CH3, Arg, Pro and Glu 
C~H2,C~H2, Tyr C~H2), 2.9-3.7 (b, 34H, Pro C~H2, 
Arg C~H~ acyl chains C~H2 and Sar N-CH3), 3.8-4.6 (b, 
22H, Tyr, Arg, Pro, Glu, Ile, Sar and Leu C~H), 6.7-7.2 
(b, 4H, Tyr +), 7.5-7.7 (m, 6H, Arg, Leu, Ile,Glu, Tyr 
NH). 
2.3. Fluorescence depolarization and quenching 
An aliquot of a tetrahydrofuran solution of DPH was 
added to the peptide derivatives in a Tris buffer solution 
(10 mM, pH 7.4, 0.1 mM EDTA). The solution was 
incubated for 30 min at prescribed temperature, and fluo- 
rescence depolarization was measured by a Hitachi MPF-4 
fluorescence spectrophotometer equipped with a home- 
made apparatus for the depolarization measurement [16], 
[DPH] = 0.5 p~M, [peptide] = 10 IxM. Excitation and mon- 
itoring wavelengths were 380 and 435 nm, respectively. 
Fluorescence anisotropy is related with an effective vol- 
ume of a spherical molecule according to Eq. (1) [17]. 
l / r=  (l/r0)[1 + (1) 
r, k B, T, "r, "q and v represent fluorescence anisotropy, 
Boltzman factor, temperature, fluorescence life time, vis- 
cosity and the effective volume of the molecule, respec- 
tively. The plot of 1/r  and (kBTT)/("q%), where 'r 0 is 
fluorescence life time at 25°C, gives a straight line, and v 
is calculated from the slope, ( l / r0 ) (%/v) .  
The peptides (30 ~M) were incubated overnight with 
DMPC liposome ([DMPC] = 6.0 mM) in a Tris buffer 
solution (10 mM, pH 7.4, 0.1 mM EDTA). Fluorescence 
spectra of the dispersion were measured with increasing 
amount of acrylamide at 30°C. Excitation and monitoring 
wavelengths were 276 and 305 nm, respectively. 
2.4. Immobilization of peptides to liposome 
DMPC liposome was prepared by a sonication method. 
A Tris buffer solution (10 mM, pH 7.4, EDTA 0.1 mM) 
was added to a dry thin film of DMPC, and the mixture 
was sonicated by a probe-type sonicator at 35°C under N 2 
atmosphere. The suspension was centrifuged at 100000 × 
g. Peptide derivatives were incubated overnight with a 
prescribed concentration f DMPC liposome at 30°C. 
2.5. Distribution of the neurotensin derivatiues in DMPC 
liposome 
(i) Examination by a column method: The peptides (30 
IxM) were incubated overnight with DMPC liposome (6.0 
mM) at 30°C, and the suspension was eluted through a 
Sephadex G-50 column. The peptides were detected by 
fluorescence at 305 nm. Excitation wavelength was 276 
nm. The elution of DMPC liposome was also detected by 
fluorescence at305 nm due to light scattering. 
(ii) Determination of the amount of peptides not in- 
cluded in liposome: The peptides (20 txM) in the presence 
or the absence of DMPC liposome (4.0 mM) were incu- 
bated at 30°C overnight. The suspension was filtrated 
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through a Millipore filter by centrifugation at 15 000 X g 
(Ultrafree C3TK; cut-off molecular weight, 30000). The 
amount of peptides was determined before and after the 
filtration by the fluorescence measurement. Excitation and 
monitoring wavelengths were 276 and 305 nm, respec- 
tively. 
2.6. Preparation of bovine-brain homogenate 
The receptor affinity of the peptides was determined by 
using bovine-brain homogenate, which was prepared by a 
conventional method [18]. All operations were carried out 
in a cold room. Bovine brain was chopped and suspended 
in a buffer solution (10 mM Hepes (pH 7.5), 1 mM EDTA, 
300 mM sucrose, 0.5 mM dithiothreitol, 1 mM benzami- 
dine-HCl, 0.3 mM phenylmethylsulfonyl fluoride). The 
suspension was homogenized by a Polytron (Kinematica, 
Switzerland) and a glass-Teflon homogenizer, and was 
centrifuged at 1000 × g for 12 min. The supernatant ob- 
tained was centrifuged at 27000 × g for 40 min. The 
precipitate was resuspended by using a glass-Teflon ho- 
mogenizer in the above buffer solution without containing 
sucrose and phenylmethylsulfonyl fluoride. After recen- 
trifugation, the precipitate was resuspended in the latter 
buffer solution and stored at -85°C. 
2.7. Receptor affini~ 
The buffer solution for assay was Tes-KOH buffer (10 
mM, pH 7.5) containing EGTA-K + (1 mM), bacitracin 
(0.01%), soybean trypsin inhibitor (0.002 wt%), benzami- 
dine-HC1 (1 raM), 1,10-phenanthroline (1 raM) and bovine 
serum albumin (0.02 wt%). A test tube with a total volume 
of 300 ~1 containing the membrane (0.5-1 mg/ml  pro- 
teins), 2.5 nM 3H-labeled neurotensin and different con- 
centrations of the neurotensin derivatives was used in the 
binding experiments. The suspension was incubated at 
20°C for 1 h. The binding was terminated by the addition 
of 2 ml of ice-cold Tris buffer solution (50 mM, pH 7.4), 
followed by filtration under reduced pressure through 
Whatman GF/C  glass filter. Tubes and filters were washed 
three times with 2 ml of ice-cold Tris buffer solution. The 
filters were immersed in 5 ml of Clear-sol (Nakalai Tesque, 
Japan) scintillation solution, and the radioactivity was 
counted on an LSC-1000 13 counter. Nonspecific binding 
was estimated in parallel experiments in the presence of an 
excess amount (1 ~M) of unlabeled neurotensin. Each 
assay was performed three times, and the average values 
and the standard eviations were determined. 
2.8. Observation of cells by fluorescence microscope 
Neuroblastoma NGI08-5 cells were kindly provided by 
Dr. Haruhiro Higashida (Department of Medicine, 
Kanazawa University, Kanazawa, Japan). Cells were cul- 
tured at 37°C in DMEM (Gibco, USA) supplemented with 
5% fetal calf serum and 1% HAT (Gibco, 0.1 mM hypox- 
anthine, 1 I~M aminopterin and 16 IxM thymidine), in a 
humidified atmosphere of air containing 10% CO 2. The 
cells were detached from the culture dishes by incubation 
with Dulbecco's PBS( - )  (Nissui Pharmaceutical, Japan) 
buffer at 37°C for 5 min, and the suspension was cen- 
trifuged at 1000 × g for 10 min. The cells were suspended 
in DMEM containing 5% fetal calf serum and allowed to 
grow for one day under the standard culture conditions as 
described above. Then, the medium was removed from the 
plates, and the cells were incubated in 3 mM DMEM (pH 
7.4) containing the peptide derivatives immobilized in 
DMPC liposome, which were labelled with 5 mol% of 
Rho-DPPE. The incubation was carried out at 37°C for 1 
h, and stopped by removing the medium and cooling. The 
cells were observed with a BH-2 optical and fluorescent 
microscope (Olympus, Japan). 
3. Results and discussion 
3.1. Neurotensin derivatives in water 
A dioctadecyl group was connected to N-terminal side 
of neurotensin 8-13 fragment hrough hydrophilic spacer 
chain of various lengths. The neurotensin derivatives have 
an amphiphilic structure consisting of the hydrophilic neu- 
rotensin fragment and spacer chain and the hydrophobic 
dioctadecyl group. The amphiphilic structure may promote 
assembly formation in water, which was investigated by 
using a hydrophobic fluorescent probe, DPH. DPH does 
not fluoresce in water, but fluoresces intensively in a 
hydrophobic environment. In the presence of the neu- 
rotensin derivatives in water, DPH fluoresces intensively, 
indicating incorporation of the probe into a hydrophobic 
environment formed by the assembly of neurotensin 
derivatives. 
The size of the assembly was evaluated by measuring 
fluorescence depolarization of DPH incorporated in the 
assembly, which is related to the Brownian motion of the 
assembly in water. Fluorescence depolarization of DPH in 
the peptide assembly was measured at varying tempera- 
tures from 15°C to 45°C. In the cases of DONT, D3NT, 
and D6NT, fluorescence intensity of DPH became signifi- 
cantly weak with rising temperature, resulting ultimately in 
a large fluctuation of fluorescence depolarization. It is 
considered that DONT, D3NT, and D6NT form unstable 
aggregate in water. On the other hand, fluorescence depo- 
larization of DPH incorporated in D9NT assembly was 
measured to a quantitative level. The plot of 1/r  vs. 
(kBT'r)/('q'r o) gave a straight line (Fig. 2). Assuming that 
the peptide assembly is spherical, % is 10.5 ns [19], and 
the motion of DPH bound in the assembly is severely 
restricted, the radius of the assembly was calculated to be 
30 A from the slope [17]. However, since DPH may be 
allowed to move in the assembly, the radius should be 
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Fig. 2. Fluorescence depolarization of DPH in the presence of D9NT in a 
Tris buffer solution• The reciprocal of fluorescence anisotropy (r) at 
various temperatures is plotted against (kBT'r)/('q'ro). "r/'r 0 is deter- 
mined by (lp +2t~)/ ( lp  +21~), where lp and 14 represent fluorescence 
intensities of parallel and vertical orientation, respectively, lp and I,. are 
those at 298 K. 
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Fig. 4. The Stern-Volmer plot of fluorescence quenching with acryl- 
amide of the neurotensin derivatives in the presence of DMPC liposome. 
DONT (0) ,  D3NT (z~), D6NT (A), D9NT (•), and neurotensin 8-13 
fragment in a Tris buffer solution ((3). 
underestimated. The molecular length of D9NT should be 
in the range of 30-60 A on the basis of molecular model- 
ing, which depends on the conformation of the neurotensin 
fragment and the spacer chain. Consequently, it is reason- 
able to consider that D9NT takes a spherical micelle in 
water. 
3.2. Interaction of neurotensin derivatives with liposome 
The neurotensin derivatives were incubated in the pres- 
ence of DMPC liposome overnight, and the distribution of 
the derivatives in the liposome was investigated. The 
elution profile of the dispersion of D3NT and DMPC 
liposome through a gel chromatography column showed a 
peak at the same position as DMPC liposome (Fig. 3), 
indicating that D3NT was bound to DMPC liposome. 
The distribution rate of the derivatives to DMPC lipo- 
some was studied by measuring the amount of the peptide 
2000 • , , , • i , i • 
~ 1000 
0 ' ' "111  
0 10 20 30 40 50 
Fract ion  Number  
Fig. 3. The elution profile of DMPC liposome (0), D3NT immobilized 
on DMPC liposome (O), and neurotensin ([]) through a Sephadex G-50 
column. Experimental conditions are described inthe text. 
not included in liposome. When the neurotensin deriva- 
tives were incubated in the presence of DMPC liposome 
overnight and filtrated, the filtrate did not show fluores- 
cence of Tyr residue of the neurotensin fragment. On the 
other hand, in the absence of DMPC liposome, the amounts 
of the derivatives found in the filtrate were 65% for DONT, 
91% for D3NT, 82% for D6NT, and 84% for D9NT. The 
relatively low value for DONT is probably due to aggrega- 
tion in a buffer solution, because DONT is most hydropho- 
bic among the derivatives. Therefore, it is concluded that 
nearly all of the neurotensin fragment derivatives are 
immobilized on DMPC liposome in water. 
3.3. Location of neurotensin fragment in liposome 
The location of the neurotensin message segment im- 
mobilized on DMPC liposome was determined by quench- 
ing of Tyr fluorescence of the neurotensin derivatives with 
a water-soluble quencher, acrylamide. All of the neu- 
rotensin derivatives were quenched with acrylamide in a 
similar manner to free neurotensin 8-13 fragment (Fig. 4). 
It is, therefore, considered that the neurotensin fragment of 
the derivatives is exposed to water phase with the dioc- 
tadecyl group anchoring to the hydrophobic core of DMPC 
liposome. 
3.4. Receptor affinity of neurotensin derivatives immobi- 
lized on liposome 
Receptor affinity of the neurotensin derivatives immobi- 
lized on liposome was investigated by the competitive 
binding assay using bovine brain homogenate. Fig. 5 shows 
the competitive inhibition of [3H]neurotensin binding to 
the receptor with varying concentrations of peptide. The 
inhibition curve shifts to lower concentrations of DONT 
upon immobilization on liposome, indicating that the re- 
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Fig. 5. Inhibition by DONT of the [3H]neu~tensin bi ding to bovine 
brain homogenate in the presence of varytllg amounts of DMPC lipo- 
some. [DMPC]/[DONT] = 0 (O), 50 (O), lif0 (ll), 200 ([]), 500 (zx), 
and 1000 (A).  
ceptor affinity of DONT increases upon immobilization. 
The receptor affinity is dependent on the molar ratio of the 
lipid and the peptide. The highest affinity was obtained at 
the molar ratio of 200, where the receptor affinity of 
DONT was 65-fold higher than that in the absence of 
liposome. 
The IC50 values of D3NT with varying molar ratios of 
the lipid and the peptide are summarized in Table 1. The 
highest affinity was also obtained at the molar ratio of 200, 
and the affinity is similar to that of the neurotensin 8 - t  
fragment. The dependence of the affinity on the molar 
ratio may be explained by multisite interactions between 
the peptides immobilized on liposome and the receptors 
located in membrane. When the molar ratio is high, simul- 
taneous binding should be difficult to occur. On the other 
hand, a high density of peptides on liposome should enable 
multisite interaction to occur easily, resulting in a high 
receptor affinity. When the density of the ligand in lipo- 
A 
13 
C 
Fig. 6. Optical (left) and fluorescence micrographs (right) of NG108-15 cells incubated with (A) DMPC liposome containing Rho-DPPE, (B) neurotensin 
8-13 fragment and DMPC liposome containing Rho-DPPE, (C) D9NT immobilized inDMPC liposome containing Rho-DPPE. 
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Table 1 
Inhibition of [3H]neurotensin binding to 
with varying [DMPC]/[D3NT] at 20°C 
neurotensin receptor by D3NT 
[DMPC]/[D3NT] a IC5o (nM) 
0 36.4±3.6 
50 18.4±3.6 
1~ 13.6±3.1 
2~ 10.0±1.4 
5~ 15.5±3.7 
1000 33.8±4.2 
25~ 29.6±5.4 
a D3NT solution of 6.10 -5 M was incubated with DMPC liposome at 
30°C overnight. 
some is very high, some ligand molecules would not 
participate in the receptor binding. Consequently, the re- 
ceptor affinity in terms of the ligand concentration may 
decrease, yielding the maximum value at the molar ratio of 
200, 
IC50~ values of the neurotensin derivatives immobilized 
on liposome at the molar ratio of 200 are summarized in 
Table 2. All the peptides raise the receptor affinity upon 
immobilization on liposome, although the receptor affinity 
of neurotensin 8-13 fragment is independent of the pres- 
ence of liposome. Notably, D9NT immobilized on lipo- 
some shows a trend of slightly higher eceptor affinity than 
the neurotensin 8-13 fragment. 
The receptor affinity changes with varying lengths of 
the spacer chain connecting the neurotensin fragment o 
the dioctadecyl group. The spacer chain is composed of 
-(Sar-Sar-Pro) n- oligopeptide, which is hydrophilic and 
flexible. The receptor affinity of the neurotensin deriva- 
tives increases with elongation of the spacer chain either in 
free or in immobilized state. This observation may be 
explained in terms of a release of receptor binding from 
steric hindrance. With elongation of the hydrophilic spacer 
chain, the neurotensin fragment of the derivative may 
extend to aqueous phase which is sterically less crowded. 
3.5. Observation of receptor binding by fluorescence mi- 
croscopy 
gated by fluorescence microscopy. Liposome was labelled 
with Rho-DPPE. NG108-15 cell was not stained by lipo- 
some containing Rho-DPPE either in the absence or in the 
presence of neurotensin 8-13 fragment (Fig. 6 (A), (B)). 
However, NG108-15 cell became fluorescent when incu- 
bated with liposome containing Rho-DPPE and D9NT 
(Fig. 6 (C)). NG108-15 cell was made fluorescent by 
liposome containing Rho-DPPE in the presence of other 
neurotensin derivatives, too. It is, therefore, concluded that 
the neurotensin derivatives are bound by receptors as being 
tightly immobilized on liposome. 
3.6. Conclusion 
The neurotensin derivatives having a dioctadecyl group 
at the N-terminal side are easily immobilized on DMPC 
liposome. The receptor affinity of the neurotensin deriva- 
tives increases upon immobilization on liposome. Espe- 
cially, the neurotensin derivative with a long hydrophilic 
spacer chain is more familiar to the receptor than the 
neurotensin 8-13 fragment. Similar results were obtained 
by enkephalin derivatives having long alkyl chains which 
were immobilized on liposome [11]. It is, therefore, con- 
cluded that the immobilization of peptide ligands on lipo- 
some is an effective way to enhance the receptor affinity 
of the multivalent ligand system. The multivalent ligand 
system will simultaneously activate neighboring receptors 
existing in a localized area within the cell membrane, 
which may result in an enhanced chemical signaling, su- 
perpotency [7] or an altered signal transduction [9] due to 
receptor-receptor interactions [20]. The biological rele- 
vance of the multivalent ligand system is under investiga- 
tion. 
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The binding of the neurotensin derivatives immobilized 
on liposome to receptors in NG108-15 cell was invest±- 
Table 2 
Inhibition of [3H]neurotensin binding to neurotensin receptor by neu- 
rotensin derivatives at 20°C 
IC 5o (nM) 
free in liposome a
Neurotensin 1-13 4.5 + 1.0 
Neurotensin 8-13 11.4+ 3.4 12.9__+ 2.8 
DONT 615 +42 70.0_+ 10 
D3NT 36.4+ 3.6 10.0+ 1.4 
D6NT 46.6+ 6.0 13.4-t- 2.7 
D9NT 27.2+ 4.1 7.0+ 2 
a [Neurotensin unit]/[DMPC] = 1:200. 
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